These anti-EGFR TKIs have demonstrated a favorable hematologic toxicity profile (e.g. less grade 3–4 neutropenia and thrombocytopenia) compared to the chemotherapeutic alternatives and can provide a treatment alternative in patients in whom a break from chemotherapy is preferred.[4, 20, 21]. This evidence concerns the gene EGFR and Decreased total neutrophil count.